Egetis Therapeutics
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
EGTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious, rare diseases with significant unmet medical needs. The company's strategy centers on advancing projects through late-stage clinical development to regulatory approval and market launch. Its leading drug candidate, Emcitate, targets MCT8 deficiency, a rare genetic disease characterized by a shortage of thyroid hormones in the brain.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-31 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Change in the number of shares and votes in Egetis Therapeutics
|
English | 58.2 KB | ||
| 2025-10-31 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Egetis Therapeutics
|
Swedish | 61.4 KB | ||
| 2025-10-23 08:00 |
Legal Proceedings Report
Egetis beviljas löpande NDA-granskning av FDA för Emcitate® (tiratricol) basera…
|
Swedish | 90.0 KB | ||
| 2025-10-23 08:00 |
Regulatory News Service
Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on …
|
English | 86.3 KB | ||
| 2025-10-02 23:40 |
Share Issue/Capital Change
Egetis Therapeutics has successfully carried out a directed share issue amounti…
|
English | 82.9 KB | ||
| 2025-10-02 23:40 |
Share Issue/Capital Change
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående …
|
Swedish | 83.7 KB | ||
| 2025-10-02 17:31 |
Share Issue/Capital Change
Egetis Therapeutics intends to carry out a directed share issue of up to 10 per…
|
English | 76.8 KB | ||
| 2025-10-02 17:31 |
Share Issue/Capital Change
Egetis Therapeutics avser att genomföra en riktad nyemission av högst 10 procen…
|
Swedish | 78.4 KB | ||
| 2025-08-21 07:00 |
Interim Report
|
Swedish | 3.7 MB | ||
| 2025-08-21 07:00 |
Interim Report
|
English | 3.4 MB | ||
| 2025-07-15 08:00 |
Regulatory News Service
Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 de…
|
English | 75.2 KB | ||
| 2025-07-15 08:00 |
Legal Proceedings Report
Egetis erhåller Breakthrough Therapy Designation från FDA för tiratricol för be…
|
Swedish | 71.1 KB | ||
| 2025-05-16 00:00 |
Annual Report (ESEF)
|
Swedish | 12.4 MB | ||
| 2025-05-06 17:59 |
Post-Annual General Meeting Information
Kommuniké från Egetis Therapeutics årsstämma 2025
|
Swedish | 55.3 KB | ||
| 2025-05-06 17:59 |
Post-Annual General Meeting Information
Bulletin from Egetis Therapeutics’ Annual General Meeting 2025
|
English | 52.3 KB |
Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Egetis Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-09 | Yilmaz Mahshid | Other | Sell | 39,753 | 268,332.75 SEK |
| 2025-01-08 | Yilmaz Mahshid | Other | Sell | 98,567 | 653,499.21 SEK |
| 2025-01-07 | Yilmaz Mahshid | Other | Sell | 74,769 | 507,681.51 SEK |
| 2024-10-07 | Nicklas Westerholm | Other | Buy | 10,142 | 43,103.50 SEK |
| 2024-10-07 | Yilmaz Mahshid | Other | Buy | 10,000 | 42,250.00 SEK |
| 2023-07-07 | Henrik Krook | Other | Buy | 33,594 | 133,704.12 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 3,616 | 14,391.68 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 2,000 | 7,920.00 SEK |
| 2023-07-05 | Christian Sonesson | Other | Buy | 1,384 | 5,452.96 SEK |
| 2023-07-04 | Nicklas Westerholm | Other | Buy | 15,350 | 60,632.50 SEK |
Peer Companies
